TNF and rheumatoid arthritis: While much of the existing evidence is focused on early RA [20], in the UK, b/tsDMARDs are typically reserved for patients with moderate or severe RA who have had an inadequate response to intensive treatments with cDMARDs already [11], at which point TNF inhibitors (TNFis) are generally tried first before other targeted therapies are considered [21].